Abeona Therapeutics Company Profile (OTCMKTS:ACCP)

About Abeona Therapeutics (OTCMKTS:ACCP)

Abeona Therapeutics logoAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ACCP
  • CUSIP: N/A
  • Web: abeonatherapeutics.com/
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -2,820.97%
  • Return on Equity: -21.61%
  • Return on Assets: -19.46%
 
Frequently Asked Questions for Abeona Therapeutics (OTCMKTS:ACCP)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the OTCMKTS under the ticker symbol "ACCP."

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H. Rouhandeh, Executive Chairman of the Board
  • Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
  • Jeffrey B. Davis, Chief Operating Officer
  • David P. Nowotnik Ph.D., Senior Vice President - Research and Development
  • Harrison G. Wehner III, Senior Vice President - Plasma
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
  • Michelle Berg, Vice President - Communications & Operations
  • Andre'a Lucca, Vice President - Communications & Operations
  • Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
  • Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of Abeona Therapeutics stock can currently be purchased for approximately $0.22.


MarketBeat Community Rating for Abeona Therapeutics (OTCMKTS ACCP)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  21
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (OTCMKTS:ACCP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Abeona Therapeutics (OTCMKTS:ACCP)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Abeona Therapeutics (OTCMKTS:ACCP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Abeona Therapeutics (OTCMKTS:ACCP)
Current Year EPS Consensus Estimate: $0.70 EPS

Dividends

Dividend History for Abeona Therapeutics (OTCMKTS:ACCP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (OTCMKTS:ACCP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Abeona Therapeutics (OTCMKTS:ACCP)
Latest Headlines for Abeona Therapeutics (OTCMKTS:ACCP)
Source:
DateHeadline
reuters.com logoBRIEF-Abeona Therapeutics receives guidance from FDA
www.reuters.com - July 18 at 3:37 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for ABO-201
www.streetinsider.com - June 29 at 8:34 PM
reuters.com logoBRIEF-Abeona Therapeutics receives FDA orphan drug designation for ABO-201 juvenile Batten disease gene therapy program
www.reuters.com - June 29 at 3:31 PM
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona's gene therapy EB-101 an Orphan Drug for rare inherited skin-blistering disorder
seekingalpha.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for EB-101 Gene Therapy for Patients with DEB
www.streetinsider.com - May 25 at 3:34 PM
seekingalpha.com logoAbeona Therapeutics Q1 revenues $186K, cash consumption $5.9M
seekingalpha.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona Therapeutics Q1 loss per share $0.13
www.reuters.com - May 16 at 3:19 PM
reuters.com logoBRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up
www.reuters.com - May 13 at 1:41 AM
nasdaq.com logoAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa
www.nasdaq.com - May 3 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces EU Orphan Drug Designation for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
www.streetinsider.com - March 8 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics announces dismissal of securities class action lawsuit
www.reuters.com - February 23 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
finance.yahoo.com - February 23 at 3:18 PM
reuters.com logoBRIEF-Abeona Therapeutics provides update from phase 1/2 MPS IIIA clinical trial
www.reuters.com - February 17 at 6:48 PM
finance.yahoo.com logoABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving …
finance.yahoo.com - February 10 at 3:19 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona …
finance.yahoo.com - February 8 at 8:22 PM
benzinga.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP...
www.benzinga.com - January 25 at 1:44 AM
seekingalpha.com logoPremarket analyst action - new coverage
seekingalpha.com - January 6 at 8:26 PM
streetinsider.com logoAbeona Therapeutics (ABEO) ABO-201 Program Granted Orphan Drug Designation in Europe
www.streetinsider.com - January 3 at 3:25 PM
zacks.com logoAbeona Therapeutics (ABEO): Strong Industry, Solid Earnings Estimate Revisions
www.zacks.com - January 3 at 8:14 AM
reuters.com logoBRIEF-Abeona Therapeutics receives orphan drug designation in the EU for ABO-201 gene therapy program
www.reuters.com - January 3 at 8:14 AM
businesswire.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Abeona Therapeutics Inc. To Contact Brower Piven Before The Lead ...
www.businesswire.com - December 30 at 1:23 AM
seekingalpha.com logoAbeona - Considerable Upside Potential With Near Term Catalysts
seekingalpha.com - December 22 at 8:18 PM
benzinga.com logoGainey McKenna & Egleston Announces A Class...
www.benzinga.com - December 17 at 1:27 AM
finance.yahoo.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Abeona Therapeutics …
finance.yahoo.com - December 17 at 1:27 AM
seekingalpha.com logoAbeona slips 8% on bearish call from Mako Research
seekingalpha.com - December 12 at 3:23 PM
seekingalpha.com logoAbeona Therapeutics beats by $0.11, misses on revenue
seekingalpha.com - November 10 at 1:40 PM
seekingalpha.com logoAbeona prices 6M-share stock offering; shares ease 2%
seekingalpha.com - October 27 at 3:31 PM
finance.yahoo.com logoAbeona Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 27 at 3:31 PM
thestreet.com logoInteresting ABEO Put And Call Options For June 2017
www.thestreet.com - October 24 at 3:18 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Updates on ABO-102 Phase 1/2 MPS IIIA; Significant Avg. GAG Reduction Noted
www.streetinsider.com - October 20 at 3:16 PM

Social

Chart

Abeona Therapeutics (ACCP) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff